SAB Biotherapeutics Marks Milestone with T1D Phase 1 Trial
SAB Biotherapeutics, Inc (Nasdaq: SABS), a pioneering clinical-stage biopharmaceutical firm specializing in a revolutionary immunotherapy platform, announced today the successful completion of the approval process
